By Adria Calatayud 
 

RELX PLC (REL.LN) confirmed Thursday its full-year guidance after posting a 4% increase in underlying revenue for the first nine months.

The Anglo-Dutch professional-information and events group said it continues to anticipate 2018 to be a year of underlying growth in revenue and in adjusted operating profit, together with growth in adjusted earnings per share on a constant-currency basis.

The company behind medical journal the Lancet and the London Book Fair said it invested 943 million pounds ($1.22 billion) in seven acquisitions in 2018 to date and sold four assets worth GBP28 million.

For the first nine months, underlying revenue grew 2% at RELX's scientific, technical and medical division--the company's largest segment--as well as 8% in risk and business analytics, 2% in legal and 6% in its exhibitions unit.

RELX said that to date, it has completed share buybacks worth GBP650 million of the previously announced GBP700 million and plans to deploy the remainder by year end.

The company's simplification of its corporate structure into a single parent company was completed on Sept. 8, RELX said.

 

Write to Adria Calatayud at adria.calatayudvaello@dowjones.com

 

(END) Dow Jones Newswires

October 25, 2018 02:25 ET (06:25 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
RELX (EU:REN)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more RELX Charts.
RELX (EU:REN)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more RELX Charts.